ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor–Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy

Introduction: Mutations in the ESR1 gene (ESR1m) are important mechanisms of resistance to endocrine therapy in estrogen receptor–positive (ER+) metastatic breast cancer and have been studied as a potential therapeutic target, as well as a predictive and prognostic biomarker. Nonetheless, the role o...

Descripción completa

Detalles Bibliográficos
Autores principales: Reinert, Tomás, Ramalho, Susana, de Vasconcelos, Vivian Castro Antunes, Silva, Leonardo Roberto, da Silva, Ana Elisa Ribeiro, de Andrade, Camila Annicchino, Kraft, Maria Beatriz de Paula Leite, Coelho, Guilherme Portela, Mandelli, Jovana, Binotto, Monique, Cabello, Cesar, de Paiva Silva, Geisilene Russano, Bines, José, Barrios, Carlos H., Ellis, Matthew J., Graudenz, Marcia Silveira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145981/
https://www.ncbi.nlm.nih.gov/pubmed/32309212
http://dx.doi.org/10.3389/fonc.2020.00342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145981/
https://www.ncbi.nlm.nih.gov/pubmed/32309212
http://dx.doi.org/10.3389/fonc.2020.00342

Ejemplares similares